Cannabis News

Tilray Ceases Work Travel, Meetings Due to Corona

Cannabis Firm Tilray to Shut Down Its Operations Because of Corona

Working as a leading Canadian pharmaceutical and cannabis firm, Tilray has released a chain of tweets on its official Twitter handle to announce the crucial decisions taken by the team in the light of the COVID-19 outbreak. The firm has halted all non-essential company traveling, including domestic as well as international flights, conference and meetings. Tilray is adamant about keeping the health, safety, and well-being of its workforce and the partner communities as a priority and so has taken the strategic step.

In its tweet, Tilray has urged its employees to opt for work from home facility to ensure minimum human gathering. The reports suggest that getting in contact with an infected person is one of the prime reasons for the transmission of the disease. Owing to this, governments and business entities around the world are encouraging people to avoid social interaction and human contact, especially in huge gatherings and events such as conferences, seminars, or parties. Corona has posed a severe threat to the world population and has been responsible for deaths at an alarming rate. The disease has been declared as a pandemic by the World Health Organization and this indicates the severity of the threat it has imposed upon us.

Tilray has affirmed that they are monitoring COVID-19 closely and are following the guidance and warnings of the government organizations diligently on a global as well as on a regional scale. The firm has encouraged its employees to take all the necessary precautionary measures and follow a healthy work and personal regime.

Based in Canada, Tilray takes pride in being the first GMP-certified medical cannabis producer to supply cannabis flowers and extracts. It is incorporated in the United States with chief operational offices headquartered in Toronto, Ontario. The firm is quite popular for being engaged in the research, cultivation, production, and distribution of medical cannabis and cannabinoids.

About the author

Mia Wilson

Mia Wilson is a science graduate and has 12 years of experience in academic research. She works as a lead content writer in our team and writes the latest content related to CBD industry. Contact her through